KEGG   DRUG: Lanadelumab
Entry
D11094                      Drug                                   
Name
Lanadelumab (USAN);
Lanadelumab (genetical recombination) (JAN);
Lanadelumab-flyo;
Takhzyro (TN)
Product
Formula
C6468H10016N1728O2012S48
Exact mass
145624.115
Mol weight
145714.225
Sequence
(Heavy chain)
EVQLLESGGG LVQPGGSLRL SCAASGFTFS HYIMMWVRQA PGKGLEWVSG IYSSGGITVY
ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAYRR IGVPRRDEFD IWGQGTMVTV
SSASTKGPSV FPLAPSSKST SGGTAALGCL VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ
SSGLYSLSSV VTVPSSSLGT QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELL
GGPSVFLFPP KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPREEQ
YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE PQVYTLPPSR
EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTTP PVLDSDGSFF LYSKLTVDKS
RWQQGNVFSC SVMHEALHNH YTQKSLSLSP G
(Light chain)
DIQMTQSPST LSASVGDRVT ITCRASQSIS SWLAWYQQKP GKAPKLLIYK ASTLESGVPS
RFSGSGSGTE FTLTISSLQP DDFATYYCQQ YNTYWTFGQG TKVEIKRTVA APSVFIFPPS
DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
(Disulfide bridge: H22-H96, H149-H205, H225-L213, H231-H'231, H234-H'234, H266-H326, H372-H430, H'22-H'96, H'149-H'205, H'225-L'213, H'266-H'326, H'372-H'430, L23-L88, L133-L193, L'23-L'88, L'133-L'193)
  Type
Peptide
Remark
Therapeutic category: 4490
ATC code: B06AC05
Product: D11094<JP/US>
Efficacy
Immunomodulator, Plasma kallikrein inhibitor
  Disease
Hereditary angioedema [DS:H01006]
  Type
Monoclonal antibody
Comment
Prevention of angioedema in patients with hereditary angioedema
Target
KLKB1 [HSA:3818] [KO:K01324]
  Pathway
hsa04610  Complement and coagulation cascades
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 B BLOOD AND BLOOD FORMING ORGANS
  B06 OTHER HEMATOLOGICAL AGENTS
   B06A OTHER HEMATOLOGICAL AGENTS
    B06AC Drugs used in hereditary angioedema
     B06AC05 Lanadelumab
      D11094  Lanadelumab (USAN) <JP/US>
USP drug classification [BR:br08302]
 Immunological Agents
  Angioedema Agents
   Kallikrein Inhibitors
    Lanadelumab
     D11094  Lanadelumab (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
 4  Agents affecting cellular function
  44  Allergic agents
   449  Miscellaneous
    4490  Miscellaneous
     D11094  Lanadelumab (USAN); Lanadelumab (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
 Enzymes
  Hydrolases (EC3)
   Serine peptidases
    KLKB1
     D11094  Lanadelumab (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11094
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D11094
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11094
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11094
Other DBs
CAS: 1426055-14-2
PubChem: 376219019
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system